Trials / Completed
CompletedNCT04608799
The Efficacy of Fycompa (Perampanel) in Children With Epilepsy
Director of Child Neurology, Department of Pediatrics, National Taiwan University Hospital
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 38 (actual)
- Sponsor
- National Taiwan University Hospital · Academic / Other
- Sex
- All
- Age
- 0 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
Fycompa (Perampanel), a new anti-epileptic drug that uses a new mechanism-AMPA receptor antagonist. Its initial indication is for local or generalized epilepsy in children and adults over 12 years old, but its effectiveness in the treatment of epilepsy in children At present, more evidence is still needed. We will study the effectiveness of Fycompa (Perampanel) in the treatment of epilepsy in children under the age of 18. It is expected that the clinical use of Fycompa (Parampanel) in Taiwan will be able to analyze and study the effectiveness of the clinical use of Fycompa (Parampanel) in the treatment of epilepsy in children, and compare it with foreign reports.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Perampanel | Efficacy of epilepsy drugs |
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2020-03-19
- Completion
- 2020-03-19
- First posted
- 2020-10-29
- Last updated
- 2020-10-29
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT04608799. Inclusion in this directory is not an endorsement.